• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA-199a-3p靶向干性相关和促有丝分裂信号通路,以抑制前列腺癌干细胞的扩增和致瘤能力。

miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.

作者信息

Liu Ruifang, Liu Can, Zhang Dingxiao, Liu Bigang, Chen Xin, Rycaj Kiera, Jeter Collene, Calhoun-Davis Tammy, Li Yandong, Yang Tao, Wang Junchen, Tang Dean G

机构信息

Cancer Stem Cell Institute, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX 78957, USA.

出版信息

Oncotarget. 2016 Aug 30;7(35):56628-56642. doi: 10.18632/oncotarget.10652.

DOI:10.18632/oncotarget.10652
PMID:27447749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5302940/
Abstract

Human cancers exhibit significant cellular heterogeneity featuring tumorigenic cancer stem cells (CSCs) in addition to more differentiated progeny with limited tumor-initiating capabilities. Recent studies suggest that microRNAs (miRNAs) regulate CSCs and tumor development. A previous library screening for differential miRNA expression in CD44+ (and other) prostate CSC vs. non-CSC populations identified miR-199a-3p to be among the most highly under-expressed miRNAs in CSCs. In this study, we characterized the biological functions of miR-199a-3p in CD44+ prostate cancer (PCa) cells and in tumor regeneration. Overexpression of miR-199a-3p in purified CD44+ or bulk PCa cells, including primary PCa, inhibited proliferation and clonal expansion without inducing apoptosis. miR-199a-3p overexpression also diminished tumor-initiating capacities of CD44+ PCa cells as well as tumor regeneration from bulk PCa cells. Importantly, inducible miR-199a-3p expression in pre-established prostate tumors in NOD/SCID mice inhibited tumor growth. Using target prediction program and luciferase assays, we show mechanistically that CD44 is a direct functional target of miR-199a-3p in PCa cells. Moreover, miR-199a-3p also directly or indirectly targeted several additional mitogenic molecules, including c-MYC, cyclin D1 (CCND1) and EGFR. Taken together, our results demonstrate how the aberrant loss of a miRNA-mediated mechanism can lead to the expansion and tumorigenic activity of prostate CSCs, further supporting the development and implementation of miRNA mimics for cancer treatment.

摘要

人类癌症表现出显著的细胞异质性,除了具有有限肿瘤起始能力的更多分化后代外,还具有致瘤性癌症干细胞(CSCs)。最近的研究表明,微小RNA(miRNAs)调节CSCs和肿瘤发展。先前一项针对CD44 +(及其他)前列腺CSC与非CSC群体中差异miRNA表达的文库筛选确定,miR-199a-3p是CSCs中表达水平最低的miRNAs之一。在本研究中,我们表征了miR-199a-3p在CD44 +前列腺癌(PCa)细胞和肿瘤再生中的生物学功能。在纯化的CD44 +或大量PCa细胞(包括原发性PCa)中过表达miR-199a-3p可抑制增殖和克隆扩增,而不诱导细胞凋亡。miR-199a-3p过表达还降低了CD44 + PCa细胞的肿瘤起始能力以及大量PCa细胞的肿瘤再生能力。重要的是,在NOD/SCID小鼠预先建立的前列腺肿瘤中诱导miR-199a-3p表达可抑制肿瘤生长。使用靶标预测程序和荧光素酶测定,我们从机制上表明CD44是PCa细胞中miR-199a-3p的直接功能靶标。此外,miR-199a-3p还直接或间接靶向其他几种促有丝分裂分子,包括c-MYC、细胞周期蛋白D1(CCND1)和表皮生长因子受体(EGFR)。综上所述,我们的结果证明了miRNA介导机制的异常缺失如何导致前列腺CSCs的扩增和致瘤活性,进一步支持了miRNA模拟物用于癌症治疗的研发和应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/394f9014e2aa/oncotarget-07-56628-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/4ff2971ddae5/oncotarget-07-56628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/44ced5041dd6/oncotarget-07-56628-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/bf7f365a0012/oncotarget-07-56628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/614c8ec03aa1/oncotarget-07-56628-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/d0f34d29058c/oncotarget-07-56628-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/596c3c0aeeb4/oncotarget-07-56628-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/394f9014e2aa/oncotarget-07-56628-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/4ff2971ddae5/oncotarget-07-56628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/44ced5041dd6/oncotarget-07-56628-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/bf7f365a0012/oncotarget-07-56628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/614c8ec03aa1/oncotarget-07-56628-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/d0f34d29058c/oncotarget-07-56628-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/596c3c0aeeb4/oncotarget-07-56628-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16b/5302940/394f9014e2aa/oncotarget-07-56628-g007.jpg

相似文献

1
miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.微小RNA-199a-3p靶向干性相关和促有丝分裂信号通路,以抑制前列腺癌干细胞的扩增和致瘤能力。
Oncotarget. 2016 Aug 30;7(35):56628-56642. doi: 10.18632/oncotarget.10652.
2
MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling.miR-199a-5p 通过靶向 Sirt1 和 CD44ICD 切割信号抑制皮肤鳞状细胞癌干细胞的干性。
Cell Cycle. 2020 Jan;19(1):1-14. doi: 10.1080/15384101.2019.1689482. Epub 2019 Dec 6.
3
miR-199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1.miR-199a/214簇通过靶向TBL1XR1增强前列腺癌对尼妥珠单抗的敏感性。
Kaohsiung J Med Sci. 2023 Dec;39(12):1178-1189. doi: 10.1002/kjm2.12758. Epub 2023 Sep 29.
4
miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment.miR-199a-3p 抑制极光激酶 A 并减弱前列腺癌生长:前列腺癌治疗的新途径。
Am J Pathol. 2014 May;184(5):1541-9. doi: 10.1016/j.ajpath.2014.01.017. Epub 2014 Mar 11.
5
MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.微小 RNA-199a 通过靶向 CD44 抑制卵巢癌起始细胞的致瘤性和多药耐药性。
FEBS J. 2012 Jun;279(11):2047-59. doi: 10.1111/j.1742-4658.2012.08589.x. Epub 2012 Apr 24.
6
MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression.微小RNA-141-3p通过抑制克鲁ppel样因子9的表达促进前列腺癌细胞增殖。
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1381-1386. doi: 10.1016/j.bbrc.2016.12.045. Epub 2016 Dec 9.
7
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.微小 RNA miR-34a 通过直接抑制 CD44 抑制前列腺癌干细胞和转移。
Nat Med. 2011 Feb;17(2):211-5. doi: 10.1038/nm.2284. Epub 2011 Jan 16.
8
MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.微小 RNA-320 通过下调 Wnt/β-连环蛋白信号通路抑制前列腺癌细胞的干细胞样特性。
Carcinogenesis. 2013 Mar;34(3):530-8. doi: 10.1093/carcin/bgs371. Epub 2012 Nov 26.
9
MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.miR-199a/b-3p 通过下调 PAK4/MEK/ERK 信号通路抑制胃癌细胞增殖。
BMC Cancer. 2018 Jan 5;18(1):34. doi: 10.1186/s12885-017-3949-2.
10
miRNA-708 control of CD44(+) prostate cancer-initiating cells.miRNA-708 对 CD44(+)前列腺癌起始细胞的调控。
Cancer Res. 2012 Jul 15;72(14):3618-30. doi: 10.1158/0008-5472.CAN-12-0540. Epub 2012 May 2.

引用本文的文献

1
Therapeutic implications of cancer stem cells in prostate cancer.癌症干细胞在前列腺癌中的治疗意义。
Cancer Biol Med. 2023 Jun 5;20(6):401-20. doi: 10.20892/j.issn.2095-3941.2022.0714.
2
State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.针对前列腺癌中癌症干细胞的前沿治疗策略。
Front Oncol. 2023 Mar 9;13:1059441. doi: 10.3389/fonc.2023.1059441. eCollection 2023.
3
Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.间充质干细胞衍生的外泌体作为在癌症治疗中递送微小RNA的新工具。

本文引用的文献

1
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.对人类前列腺癌细胞的表型、功能和致瘤异质性进行系统剖析。
Oncotarget. 2015 Sep 15;6(27):23959-86. doi: 10.18632/oncotarget.4260.
2
EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.表皮生长因子受体通过下调miR-1并激活TWIST1促进前列腺癌骨转移。
Cancer Res. 2015 Aug 1;75(15):3077-86. doi: 10.1158/0008-5472.CAN-14-3380. Epub 2015 Jun 12.
3
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
Front Bioeng Biotechnol. 2022 Sep 26;10:956563. doi: 10.3389/fbioe.2022.956563. eCollection 2022.
4
Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.利用整合生物信息学方法进行基因表达、关键途径和调控网络分析鉴定前列腺癌的潜在关键基因。
Genes (Basel). 2022 Apr 8;13(4):655. doi: 10.3390/genes13040655.
5
MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .微小RNA-199a-3p通过下调……促进三阴性乳腺癌的药物敏感性。
Am J Transl Res. 2022 Mar 15;14(3):2021-2036. eCollection 2022.
6
Understanding and targeting prostate cancer cell heterogeneity and plasticity.理解和靶向前列腺癌细胞异质性和可塑性。
Semin Cancer Biol. 2022 Jul;82:68-93. doi: 10.1016/j.semcancer.2021.11.001. Epub 2021 Nov 26.
7
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.治疗抵抗、癌症复发和转移中的休眠(慢循环)癌细胞。
Semin Cancer Biol. 2022 Jan;78:90-103. doi: 10.1016/j.semcancer.2021.04.021. Epub 2021 May 9.
8
Identification and Validation of New Cancer Stem Cell-Related Genes and Their Regulatory microRNAs in Colorectal Cancerogenesis.结直肠癌发生中新的癌症干细胞相关基因及其调控性微小RNA的鉴定与验证
Biomedicines. 2021 Feb 11;9(2):179. doi: 10.3390/biomedicines9020179.
9
Downregulation of miR-199a-3p in Hepatocellular Carcinoma and Its Relevant Molecular Mechanism via GEO, TCGA Database and In Silico Analyses.肝细胞癌中 miR-199a-3p 的下调及其通过 GEO、TCGA 数据库和计算机分析的相关分子机制。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820979670. doi: 10.1177/1533033820979670.
10
Non-coding RNA therapeutics for cardiac regeneration.非编码 RNA 治疗心脏病再生。
Cardiovasc Res. 2021 Feb 22;117(3):674-693. doi: 10.1093/cvr/cvaa071.
缺氧相关的微小RNA miR-199a-3p在卵巢癌中发挥肿瘤抑制功能。
Oncotarget. 2015 May 10;6(13):11342-56. doi: 10.18632/oncotarget.3604.
4
MicroRNAs in cancer: biomarkers, functions and therapy.微小 RNA 与癌症:生物标志物、功能与治疗。
Trends Mol Med. 2014 Aug;20(8):460-9. doi: 10.1016/j.molmed.2014.06.005. Epub 2014 Jul 12.
5
Regulation of microRNA biogenesis.miRNA 生物发生的调控。
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24. doi: 10.1038/nrm3838. Epub 2014 Jul 16.
6
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.miR-199a-3p在甲状腺乳头状癌中发挥肿瘤抑制功能。
Oncotarget. 2014 May 15;5(9):2513-28. doi: 10.18632/oncotarget.1830.
7
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.在去势抵抗性前列腺癌中靶向治疗 BET 溴结构域蛋白。
Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.
8
miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment.miR-199a-3p 抑制极光激酶 A 并减弱前列腺癌生长:前列腺癌治疗的新途径。
Am J Pathol. 2014 May;184(5):1541-9. doi: 10.1016/j.ajpath.2014.01.017. Epub 2014 Mar 11.
9
Evolution of the cancer stem cell model.癌症干细胞模型的演变。
Cell Stem Cell. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006.
10
Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.鉴定前列腺癌中细胞周期蛋白 D1 网络,该网络拮抗上皮-间充质抑制。
Cancer Res. 2014 Jan 15;74(2):508-19. doi: 10.1158/0008-5472.CAN-13-1313. Epub 2013 Nov 26.